Yakov Rotshteyn

1.8k total citations
21 papers, 1.4k citations indexed

About

Yakov Rotshteyn is a scholar working on Molecular Biology, Pharmacology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Yakov Rotshteyn has authored 21 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 5 papers in Pharmacology and 4 papers in Cellular and Molecular Neuroscience. Recurrent topics in Yakov Rotshteyn's work include Radiopharmaceutical Chemistry and Applications (4 papers), Prostate Cancer Treatment and Research (4 papers) and Ion Channels and Receptors (3 papers). Yakov Rotshteyn is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (4 papers), Prostate Cancer Treatment and Research (4 papers) and Ion Channels and Receptors (3 papers). Yakov Rotshteyn collaborates with scholars based in United States, Canada and United Kingdom. Yakov Rotshteyn's co-authors include R Parikh, Peter L. Bullock, Roslida Abd Hamid, Kenneth J. Valenzano, Laykea Tafesse, Mohamed Hachicha, S. William Zito, William C. Olson, Stephen Morris and Joseph W. Francis and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and The Journal of Infectious Diseases.

In The Last Decade

Yakov Rotshteyn

21 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yakov Rotshteyn United States	15	409	274	266	257	252	21	1.4k
Rocı́o Sancho Spain	26	1.0k 2.5×	288 1.1×	83 0.3×	181 0.7×	102 0.4×	47	2.2k
Thomas Weiser Germany	26	1.1k 2.7×	192 0.7×	476 1.8×	48 0.2×	325 1.3×	76	2.3k
Nicola Costa Italy	22	387 0.9×	70 0.3×	334 1.3×	31 0.1×	160 0.6×	36	1.3k
Enilton A. Camargo Brazil	24	369 0.9×	179 0.7×	69 0.3×	44 0.2×	332 1.3×	93	1.6k
Arti Parihar United States	16	602 1.5×	107 0.4×	141 0.5×	93 0.4×	347 1.4×	25	1.6k
Manoj C. Desai United States	24	1.4k 3.4×	135 0.5×	1.0k 3.8×	31 0.1×	399 1.6×	71	2.8k
Satoshi Mohri Japan	25	975 2.4×	41 0.1×	89 0.3×	80 0.3×	168 0.7×	130	2.2k
Erik Björk Sweden	32	531 1.3×	79 0.3×	158 0.6×	116 0.5×	89 0.4×	57	2.4k
Tong‐Rong Jan Taiwan	27	490 1.2×	454 1.7×	100 0.4×	21 0.1×	159 0.6×	61	1.8k
Szilvia Veszelka Hungary	30	687 1.7×	80 0.3×	261 1.0×	36 0.1×	284 1.1×	57	2.5k

Countries citing papers authored by Yakov Rotshteyn

Since Specialization

Citations

This map shows the geographic impact of Yakov Rotshteyn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yakov Rotshteyn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yakov Rotshteyn more than expected).

Fields of papers citing papers by Yakov Rotshteyn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yakov Rotshteyn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yakov Rotshteyn. The network helps show where Yakov Rotshteyn may publish in the future.

Co-authorship network of co-authors of Yakov Rotshteyn

This figure shows the co-authorship network connecting the top 25 collaborators of Yakov Rotshteyn. A scholar is included among the top collaborators of Yakov Rotshteyn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yakov Rotshteyn. Yakov Rotshteyn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rotshteyn, Yakov, François Mercier, René Bruno, et al.. (2013). Correlation of PSMA ADC exposure with reduction in tumor growth rate determined using serial PSA measurements from a phase I clinical trial.. Journal of Clinical Oncology. 31(15_suppl). e16047–e16047. 2 indexed citations

Rotshteyn, Yakov, François Mercier, Robert D. Bruno, et al.. (2013). Abstract B215: Correlation of PSMA ADC exposure with reduction in tumor growth rate determined using serial PSA measurements from a Phase I clinical trial.. Molecular Cancer Therapeutics. 12(11_Supplement). B215–B215. 1 indexed citations

Coburn, Glen A., D. H. Paul, Yakov Rotshteyn, et al.. (2012). Novel Small-Molecule Inhibitors of Hepatitis C Virus Entry Block Viral Spread and Promote Viral Clearance in Cell Culture. PLoS ONE. 7(4). e35351–e35351. 11 indexed citations

Petrylak, Daniel P., Philip W. Kantoff, Yakov Rotshteyn, et al.. (2011). Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in taxane-refractory prostate cancer.. Journal of Clinical Oncology. 29(7_suppl). 158–158. 10 indexed citations

Rotshteyn, Yakov, Thomas A. Boyd, & Chun‐Su Yuan. (2011). Methylnaltrexone bromide: research update of pharmacokinetics following parenteral administration. Expert Opinion on Drug Metabolism & Toxicology. 7(2). 227–235. 11 indexed citations

Chandrasekaran, Appavu, Zeen Tong, Hongshan Li, et al.. (2010). Metabolism of Intravenous Methylnaltrexone in Mice, Rats, Dogs, and Humans. Drug Metabolism and Disposition. 38(4). 606–616. 24 indexed citations

Jacobson, Jeffrey M., Melanie Thompson, Jacob Lalezari, et al.. (2010). Anti–HIV‐1 Activity of Weekly or Biweekly Treatment with Subcutaneous PRO 140, a CCR5 Monoclonal Antibody. The Journal of Infectious Diseases. 201(10). 1481–1487. 76 indexed citations

Tong, Zeen, Appavu Chandrasekaran, Hongshan Li, et al.. (2010). In Vitro Metabolism and Identification of Human Enzymes Involved in the Metabolism of Methylnaltrexone. Drug Metabolism and Disposition. 38(5). 801–807. 20 indexed citations

Jacobson, Jeffrey M., Jacob Lalezari, Melanie Thompson, et al.. (2010). Phase 2a Study of the CCR5 Monoclonal Antibody PRO 140 Administered Intravenously to HIV-Infected Adults. Antimicrobial Agents and Chemotherapy. 54(10). 4137–4142. 80 indexed citations

10.

Valenzano, Kenneth J., Laykea Tafesse, Gary Lee, et al.. (2005). Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology. 48(5). 658–672. 233 indexed citations

11.

Tafesse, Laykea, Qun Sun, Kenneth J. Valenzano, et al.. (2004). Synthesis and evaluation of pyridazinylpiperazines as vanilloid receptor 1 antagonists. Bioorganic & Medicinal Chemistry Letters. 14(22). 5513–5519. 36 indexed citations

12.

Whiteside, Garth T., James Harrison, Michelle Pearson, et al.. (2004). DiPOA ([8-(3,3-Diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic Acid), a Novel, Systemically Available, and Peripherally Restricted Mu Opioid Agonist with Antihyperalgesic Activity: II. In Vivo Pharmacological Characterization in the Rat. Journal of Pharmacology and Experimental Therapeutics. 310(2). 793–799. 21 indexed citations

13.

Hamid, Roslida Abd, et al.. (2004). Comparison of alamar blue and MTT assays for high through-put screening. Toxicology in Vitro. 18(5). 703–710. 457 indexed citations

14.

Valenzano, Kenneth J., Wendy Miller, Zhengming Chen, et al.. (2004). DiPOA ([8-(3,3-Diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic Acid), a Novel, Systemically Available, and Peripherally Restricted Mu Opioid Agonist with Antihyperalgesic Activity: I. In Vitro Pharmacological Characterization and Pharmacokinetic Properties. Journal of Pharmacology and Experimental Therapeutics. 310(2). 783–792. 15 indexed citations

15.

Rotshteyn, Yakov & S. William Zito. (2004). Application of modified in vitro screening procedure for identifying herbals possessing sulfonylurea-like activity. Journal of Ethnopharmacology. 93(2-3). 337–344. 37 indexed citations

16.

Höfer, Peter, Domenico Spina, Gary Douglas, et al.. (2003). Pharmacology of a new cyclic nucleotide phosphodiesterase type 4 inhibitor, V11294. Pulmonary Pharmacology & Therapeutics. 16(2). 97–104. 13 indexed citations

17.

Valenzano, Kenneth J., Elfrida R. Grant, Gang Wu, et al.. (2003). N-(4-Tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine -1(2 H)-carbox-amide (BCTC), a Novel, Orally Effective Vanilloid Receptor 1 Antagonist with Analgesic Properties: I. In Vitro Characterization and Pharmacokinetic Properties. Journal of Pharmacology and Experimental Therapeutics. 306(1). 377–386. 219 indexed citations

18.

Sun, Qun, Laykea Tafesse, Xiaoming Zhou, et al.. (2003). 4-(2-Pyridyl)piperazine-1-carboxamides: potent vanilloid receptor 1 antagonists. Bioorganic & Medicinal Chemistry Letters. 13(20). 3611–3616. 37 indexed citations

19.

Spina, Domenico, Alan J. Miller, K. Viner Smith, et al.. (2002). Pharmacokinetic and pharmacodynamic profile following oral administration of the phosphodiesterase (PDE)4 inhibitor V11294A in healthy volunteers. British Journal of Clinical Pharmacology. 54(5). 478–484. 19 indexed citations

20.

Rotshteyn, Yakov, et al.. (1996). A Highly Sensitive Assay for the Simultaneous Determination of Morphine, Morphine-3-Glucuronide, and Morphine-6-Glucuronide in Human Plasma by High-Performance Liquid Chromatography with Electrochemical and. Therapeutic Drug Monitoring. 18(2). 179–188. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact